A Coccidioides immitis Ab IgG test detects immunoglobulin G antibodies your immune system produces against Coccidioides, the soil-dwelling fungus responsible for coccidioidomycosis, commonly called Valley fever. A positive IgG result generally indicates that your body has mounted an immune response to the fungus, pointing toward an established or recent infection rather than the very earliest stage of illness. But the test’s real-world performance varies widely depending on which commercial kit a lab uses, and the false-negative rate is high enough to catch many clinicians off guard.
What the Test Actually Measures
When Coccidioides spores are inhaled and convert into their parasitic form inside the lungs, the fungal cells display surface proteins that trigger an antibody response. One well-studied target is a glycoprotein found on the outer wall of the fungal spherule. Research has shown that this surface component reacts with IgG antibodies in the blood of people with confirmed coccidioidomycosis.1PubMed Central. Immunoreactivity of a surface wall fraction produced by spherules of Coccidioides immitis The same surface glycoprotein also stimulates cellular immune responses, making it a key antigen in both antibody-based testing and vaccine research.2PubMed. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses
In clinical practice, the IgG test is typically ordered alongside or after an IgM test. IgM antibodies tend to appear first, sometimes within a couple of weeks of symptom onset, and then fade. IgG antibodies emerge later and can persist for months or longer. When a clinician sees positive IgG without IgM, it usually suggests the infection is no longer brand-new. When both are positive, the patient may be in a transitional window. These patterns are useful but far from ironclad, because antibody timing varies from person to person.
How Different Labs Run the Test
There are two broad families of IgG testing for coccidioidomycosis. The older approach uses immunodiffusion (ID) and complement fixation (CF), which have been the reference standard for decades. The newer approach is the enzyme immunoassay (EIA), sometimes labeled ELISA, which is faster, easier to automate, and more widely available in commercial labs. Both methods look for IgG antibodies against Coccidioides antigens, but their accuracy profiles differ.
A head-to-head comparison of three commercial EIA kits found striking differences in how well each one detected IgG. The MVista kit had a sensitivity of about 87%, Meridian’s Premier kit reached roughly 71%, and the IMMY kit came in at around 47%. Specificity was more consistent, ranging from 90% to 96% across the three kits.3PubMed. Comparison of three anti-coccidioides antibody enzyme immunoassay kits for the diagnosis of coccidioidomycosis Those are not small gaps. If your lab uses one of the less sensitive kits, a negative IgG result carries considerably less reassurance than if it uses a more sensitive one. Most patients never learn which commercial kit processed their blood.
An earlier comparison showed that among patients with confirmed coccidioidomycosis, EIA for both IgG and IgM picked up every case that was also positive by traditional immunodiffusion and complement fixation testing. But the EIA was not perfectly specific: some samples from patients with blastomycosis and other non-coccidioidal diseases came back falsely positive.4PubMed Central. Comparative evaluation of commercial Premier EIA and microimmunodiffusion and complement fixation tests for Coccidioides immitis antibodies
The False-Negative Problem
One of the most important things to understand about Coccidioides IgG testing is that a negative result does not rule out infection. Research into the diagnostic limitations of antibody testing has found that false-negative rates can reach 50% to 70%, and roughly 5% of patients with symptoms of coccidioidomycosis never develop detectable antibody levels at all.5PubMed Central. Application of immunosignatures for diagnosis of valley fever That is an uncomfortable miss rate for any diagnostic test. It means a substantial number of infected people will be told their antibody test is negative, which can delay diagnosis and treatment, especially in areas where Valley fever is not routinely on clinicians’ radar.
Several factors contribute to these false negatives. Testing too early in the course of illness is a common one, since IgG may not have risen to detectable levels yet. Patients with weakened immune systems may produce less antibody overall. And there is evidence that starting antifungal treatment early can blunt the IgG response, reducing the chance of seroconversion.6PubMed Central. Top Questions in the Diagnosis and Treatment of Coccidioidomycosis If you were started on fluconazole before blood was drawn, a negative IgG is even less informative.
Cross-Reactivity With Other Fungal Infections
The IgG antibodies detected in coccidioidomycosis testing can cross-react with antigens from related fungi, particularly Histoplasma capsulatum (which causes histoplasmosis) and Blastomyces dermatitidis (which causes blastomycosis). A study of a recombinant complement fixation antigen found that half of serum samples from patients with histoplasmosis and some from blastomycosis patients reacted with the Coccidioides antigen.7PubMed Central. Recombinant Coccidioides immitis complement-fixing antigen: detection of an epitope shared by C. immitis, Histoplasma capsulatum, and Blastomyces dermatitidis This matters in regions where the geographic ranges of these fungi overlap, such as parts of the southwestern and central United States. A patient from Missouri who tests positive for Coccidioides IgG might actually have histoplasmosis. Confirmatory testing, culture, or clinical context is often needed to sort this out.
Cross-reactivity is not just a human problem. Veterinary IgG assays for dogs showed cross-reactive results in about 8% of dogs with histoplasmosis and about 6% with blastomycosis.8Medical Mycology. Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs The rates are lower than in the human recombinant antigen study, likely because the canine assay used a different antigen preparation. The takeaway for both species is the same: a positive IgG should be interpreted in context, not treated as proof of Valley fever in isolation.
What IgG Titers Tell You About Severity
Beyond the binary positive-or-negative result, the IgG antibody level (titer) carries prognostic information. The complement fixation test, which measures a form of IgG reactivity, has been used for decades to gauge how severe a coccidioidal infection might be. Higher titers tend to correlate with more widespread or serious disease.
A study that analyzed CF titers across different categories of coccidioidomycosis found that patients with uncomplicated lung infections had median peak titers of 1:4, while those with complicated pneumonia had titers around 1:24. Patients with disseminated disease, where the fungus has spread beyond the lungs, had median peak titers of 1:128. Coccidioidal meningitis patients had median titers of 1:32. Statistical analysis showed that the CF titer retained moderate ability to distinguish disseminated infections from milder ones.9PubMed Central. Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals In practice, clinicians tracking a patient’s CF titer over time use rising values as a warning sign that the infection may be worsening, and falling values as reassurance that treatment is working.
This is one area where the older immunodiffusion/CF approach offers something the newer EIA tests do not replicate as well. Commercial EIA kits report results as positive, negative, or equivocal, and some provide a quantitative index, but they were not designed to produce the kind of titer that has decades of clinical correlation data behind it. If your clinician needs to monitor your antibody level over time, they will typically order CF testing specifically.
C. immitis Versus C. posadasii
Although the test is often labeled “Coccidioides immitis Ab IgG,” two species of Coccidioides actually cause human disease: C. immitis, found mainly in California’s Central Valley, and C. posadasii, which predominates in Arizona, Texas, Mexico, and Central and South America. The two species are so closely related that their proteins are more than 90% identical, and standard serologic tests cannot distinguish between them.10PubMed Central. Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity From a practical standpoint, an IgG test result is the same regardless of which species infected you. Treatment decisions do not hinge on distinguishing the two. If species identification matters for epidemiologic or research purposes, genetic testing rather than serology is needed.
Pregnancy and IgG Testing
Pregnant women who live in or travel through areas where Coccidioides is common deserve particular attention. The risk of the infection spreading beyond the lungs increases as pregnancy progresses, with the third trimester and the period just after delivery being the highest-risk windows. The mechanism likely involves changes in cellular immunity and shifting hormone levels that favor fungal growth.11PubMed Central. Coccidioidomycosis in pregnancy: Case report and literature review of associated placental lesions
From a testing perspective, this creates a difficult situation. A pregnant woman with an unexplained cough and fever in an endemic area should have coccidioidomycosis on the differential, and IgG testing is part of the workup. But because pregnancy itself modifies the immune response, antibody test results may behave differently than in non-pregnant adults. Clinicians in endemic areas generally have a lower threshold for repeating serologic tests or pursuing additional diagnostics (such as antigen testing or culture) in pregnant patients, given the high stakes of missed disseminated disease.
Pediatric Coccidioidomycosis and the Role of IgG EIA
In children, coccidioidomycosis can present similarly to other respiratory infections, making serologic testing important for distinguishing Valley fever from garden-variety pneumonia. For one of the most serious pediatric complications, coccidioidal meningitis, access to complement fixation testing can be limited in many endemic regions. Research in Mexican children with coccidioidal meningitis concluded that a positive IgG by enzyme immunoassay is sufficient for diagnosis in endemic areas when CF testing is not available.12PubMed Central. Hydrocephalus in Mexican children with Coccidioidal Meningitis: Clinical, serological, and neuroimaging findings This is a pragmatic conclusion for resource-limited settings, though in well-equipped labs, most infectious disease specialists still prefer CF titers for meningitis workup because of the severity-tracking advantage described above.
New Rapid Tests on the Horizon
Traditional coccidioidomycosis serology takes days to weeks to come back, depending on the lab. Several groups have been developing lateral flow assays (LFAs), the same technology behind home pregnancy tests, to speed up antibody detection. A lateral flow assay targeting antibodies against a specific Coccidioides protein (CTS1) showed about 93% agreement with positive results from traditional ID and CF testing, and nearly 98% agreement with negative results, across 143 human samples. Results come back in ten minutes.13PubMed Central. Development of a rapid lateral flow assay for detection of anti-coccidioidal antibodies The same assay also worked on serum from dogs, macaques, and dolphins, hinting at broad veterinary utility.
The potential impact of a reliable point-of-care antibody test is hard to overstate for Valley fever. Most people with coccidioidomycosis first present to urgent care or a primary care office, not an infectious disease clinic. A rapid test that could flag likely cases during the initial visit would shorten the diagnostic delay that currently stretches weeks or months for many patients. These rapid assays are not yet widely deployed in clinical practice, but the development pipeline is active.
Who Gets Exposed and Why It Matters for Testing
Coccidioides lives in arid soil across the southwestern United States, northern Mexico, and parts of Central and South America. You become infected by breathing in fungal spores, typically when soil is disturbed. Activities that raise risk include military exercises in desert environments, construction work, archaeological digs, and agricultural labor.14Oxford Academic (Journal of Travel Medicine). Travel-related risk factors for coccidioidomycosis Prison work crews in endemic areas are another recognized risk group.
Understanding exposure context matters when interpreting IgG results. If you have a positive IgG and you spent two weeks doing outdoor construction in the Phoenix area, the pretest probability of true Valley fever is high, and the positive result is almost certainly real. If you have a weakly positive IgG and you have never set foot in an endemic region, the chance of a false positive from cross-reactivity or assay noise goes up considerably. The same antibody number means different things depending on the clinical story behind it.
When IgG Is Used for Dogs
Coccidioidomycosis is remarkably common in dogs living in endemic areas, particularly Arizona. Canine serology follows similar principles to human testing, and IgG EIA kits have been developed specifically for veterinary use. One such assay achieved about 89% sensitivity and 97% specificity in dogs with proven or probable infection. Combining IgG antibody testing with antigen detection pushed sensitivity to about 93%, catching a few dogs that were antibody-negative but had fungal antigen circulating in their blood or urine.15Medical Mycology. Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs
Rapid lateral flow assays have also been evaluated in dogs. A study of 56 paired serum samples found about 88% overall agreement between a point-of-care test and standard immunodiffusion serology, with good intertest reliability.16PubMed. Evaluation of a commercially available, point-of-care Coccidioides antibody lateral flow assay to aid in rapid diagnosis of coccidioidomycosis in dogs Another study found that two different lateral flow assays performed comparably to immunodiffusion, with sensitivities in the 84% to 89% range.17PubMed Central. Two Lateral Flow Assays for Detection of Anti-Coccidioidal Antibodies Show Similar Performance to Immunodiffusion in Dogs with Coccidioidomycosis For veterinarians in endemic areas, having in-clinic rapid testing means they can start treatment sooner rather than waiting days for reference lab results.
IgG Subclasses in Vaccine Research
No human vaccine for coccidioidomycosis is currently available, but research into protective immunity has revealed that IgG subclass patterns matter. In mouse models, vaccination that produced strong IgG2a and IgG2b responses, along with specific immune-cell responses in the lungs, was associated with better protection against fungal challenge.18PubMed. Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis A similar pattern appeared in work with a recombinant vaccine candidate, where vaccinated mice showed high titers of a specific IgG subclass alongside elevated interferon-gamma production early after exposure to the fungus.19PubMed. Immune response of vaccinated and non-vaccinated mice to Coccidioides posadasii infection
This line of research suggests that the IgG response is not a single monolithic thing. The particular subtypes of IgG your body generates, and whether those antibodies appear alongside a robust cellular immune response, influence how well you fight off the fungus. Dendritic cell-based immunization approaches have also been shown to boost antigen-specific IgG in mice.20PubMed. Dendritic cell-based immunization induces Coccidioides Ag2/PRA-specific immune response None of this has reached clinical use yet, but it underscores an often-overlooked point about the diagnostic IgG test: a positive IgG tells you the immune system has noticed the fungus, but it says nothing about whether the immune response is the right kind to clear the infection. Some patients seroconvert and recover; others seroconvert and progress. The test captures recognition, not necessarily protection.
Humanized Antibody Controls and Assay Standardization
One practical challenge with any antibody-based test is ensuring that different labs using different kits produce consistent results. Recent work has introduced humanized antibodies, lab-engineered IgG and IgM molecules, as standardized positive controls for commercial EIA kits. Both humanized IgG and IgM performed well in two widely used commercial assays, meeting the threshold for a positive result in each.21PubMed Central. Clinical Laboratory Utility of a Humanized Antibody in Commercially Available Enzyme Immunoassays for Coccidioidomycosis This kind of reagent engineering is invisible to patients but matters for lab quality. If every lab running a Coccidioides IgG test uses the same reference control, it becomes easier to compare results across institutions and catch kits that are drifting out of spec.